This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 19 Apr 2016  |  Europe  |  Market Research

    European Cardiac Catheterisation Labs Market, 2016

    Changing Demographics and Reimbursement Policies to Generate Opportunities for Private Sector Growth

    The objective of this study is to present a comprehensive landscape of cardiac cathlabs in Europe, with respect to total PCI centres, pPCI centres, and key trends. The regional scope of this analysis is focused on major European countries, including Western European countries such as the United Kingdom, Germany, France, Italy, and Spain. The Easter...

    $3,000.00
  2. 18 Apr 2016  |  Europe  |  Market Research

    Visible Light Imaging and Operating Room Informatics Market, Forecast to 2019

    Growth Potential Expands as Innovative Medical Technologies Become a Must-Have Across Multiple Medical Procedures

    This study covers the global market for visible light (VL) imaging informatics and operating room (OR) imaging informatics. The latter pertain to digital and integrated operating rooms having intra-operative imaging capabilities, which are driven by increasing adoption of image-guided surgery (IGS) and minimally invasive surgery (MIS) techniques. T...

    $3,000.00
  3. 08 Apr 2016  |  North America  |  Market Research

    Global Intensive Care Unit Infrastructure—Comparative Analysis, 2015

    Trends Highlight Urgent Need for Cost-effective Critical Care Strategies, Tilt toward Higher ICU Bed Utilization Rates and Reduced Length of Stay (LOS)

    Intensive care units (ICUs) are primarily for managing patients with acute or lifethreatening disease or conditions. The critical care provided in the ICUs depends upon the resource availability such as skilled personnel and reliable advanced therapeutic and monitoring equipments. Hence, ICUs contribute to a significant amount of spending despite b...

    $3,000.00
  4. 04 Apr 2016  |  Global  |  Market Research

    Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

    Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

    This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

    $450.00
  5. 29 Mar 2016  |  Global  |  Market Research

    Top 50 Emerging Technologies: Growth Opportunities of Strategic Imperative

    Multi-billion dollar technologies ready to propel industries and transform our world

    Research Overview The Top 50 Emerging Technologies research is a comprehensive analysis of the most promising and disruptive technologies poised to impact our world in the next few years. It highlights and offers strategic guidance and actionable ideas on the hottest 50 technologies that pack maximum potential to fuel global innovation; spawn in...

    $7,500.00
  6. 18 Mar 2016  |  North America  |  Market Research

    Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery

    Additional Clinical Trials Critical to Building on Early Promise

    As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...

    $450.00
  7. 18 Mar 2016  |  North America  |  Market Research

    Vital Signs - Drug Development Focus on Genetically Modified Swine

    Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

    The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...

    $450.00
  8. 05 Jan 2016  |  Global  |  Market Research

    Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

    Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

    This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

    $450.00